Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative-to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy

Objective: The objective of this study was to determine the gadolinium (Gd) concentration remaining in human bone tissue after administration of standard clinical doses of 2 Gd-based contrast agents: Prol-lance and Omniscan. Materials and Methods: After administration of 0.1 mmol/kg of Gd chelate to patients undergoing hip replacement surgery, bone specimens were collected and analyzed, and compared with an age-matched control population without a history of Gd chelate administration. Bone specimens were collected fresh, refrigerated, and subsequently frozen. After grinding and freeze-drying, tissue digestion was performed using Teflon bombs and concentrated nitric acid. A method for analysis of Gd in bone specimens was developed and validated using inductively coupled plasma mass spectroscopy (ICP-MS). Results: Results were compared with a previous study using a different technique for analysis of the same tissue specimens. Tissue retention was 1.77 +/- 0.704 mu g Gd/g bone (n = 9) for Omniscan and 0.477 +/- 0.271 mu g Gd/g bone (n = 10) for ProHance measured by ICP-MS. These findings confirmed results from the previous ICP-AES study. Conclusion: Omniscan (Gd[DTPA-BMA]) left approximately 4 times (previous study 2.5 times) more Gd behind in bone than did ProHance (Gd[HP-DO3A]).